Valuation: CombiGene AB

Market Cap 45.34M 4.58M 4.08M 3.78M 3.44M 6.45M 434M 6.56M 17.83M 227M 17.18M 16.82M 725M P/E 2024
-1.05x
P/E 2025 -3.62x
Enterprise Value 39.5M 3.99M 3.56M 3.29M 2.99M 5.62M 378M 5.71M 15.53M 198M 14.96M 14.65M 632M EV / Sales 2024
-13.3x
EV / Sales 2025 128x
Free-Float
53.9%
Yield 2024
8.4%
Yield 2025 88.5%
1 day-1.31%
1 week-0.44%
Current month+0.89%
1 month-3.83%
3 months-0.88%
6 months+3.20%
1 week 2.15
Extreme 2.15
2.3
1 month 2.11
Extreme 2.11
2.38
Current year 1.75
Extreme 1.75
2.6
1 year 1.75
Extreme 1.75
2.87
3 years 1.27
Extreme 1.27
4.3
5 years 1.27
Extreme 1.27
16.82
10 years 1.27
Extreme 1.27
126
Manager TitleAgeSince
Chief Executive Officer 48 30/07/2025
Director TitleAgeSince
Director/Board Member 54 09/12/2024
Chairman 55 10/06/2026
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.31%-0.44%-11.02%-13.08% 4.58M
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+6.83%+10.89%+79.30% 51.2B
+0.30%-0.46%-0.03%+61.89% 51.19B
-0.98%+0.88%+24.75%+41.65% 43.93B
+0.74%+6.12%+16.71%+134.35% 41.96B
+2.06%-5.87%+238.01%+529.52% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+2.21%+27.96%+28.00% 22.5B
Average +0.63%+0.31%+41.49%+99.05% 37.24B
Weighted average by Cap. +0.87%+0.04%+45.58%+112.61%

Financials

2024 2025
Net sales 2M 202K 180K 167K 152K 284K 19.14M 289K 786K 10M 757K 741K 31.98M 304K 30.69K 27.36K 25.35K 23.04K 43.24K 2.91M 43.95K 120K 1.52M 115K 113K 4.86M
Net income -44.88M -4.53M -4.04M -3.74M -3.4M -6.38M -430M -6.49M -17.65M -225M -17M -16.64M -718M -12.36M -1.25M -1.11M -1.03M -937K -1.76M -118M -1.79M -4.86M -61.83M -4.68M -4.58M -198M
Net Debt -73.75M -7.45M -6.64M -6.15M -5.59M -10.49M -706M -10.66M -29M -369M -27.94M -27.35M -1.18B -5.84M -590K -526K -487K -443K -831K -55.92M -845K -2.3M -29.23M -2.21M -2.17M -93.44M
Projected Income Statement - Annual - CombiGene AB
Logo CombiGene AB
Larkberget AB, formerly Combigene AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
Employees
1
Date Price Change Volume
19/10/26 SEK 2.260 -1.31% 121
16/10/26 SEK 2.290 +3.62% 755
15/10/26 SEK 2.210 +1.38% 2,362
14/10/26 SEK 2.180 0.00% 1,186
13/10/26 SEK 2.180 -3.96% 1,326
  1. Stock Market
  2. Stocks
  3. LARK Stock